Keta Med Lab's website sold unapproved, misbranded ketamine liquid, troches and nasal spray to U.S. consumers without prescriptions, FDA says.
What happened
FDA reviewed the website www.ketamedlab.com on February 26, 2026 (FDA Establishment Identifier 3043543982). The agency found ketamine liquid, ketamine troches and an esketamine nasal spray offered for sale with claims that they treat depression or are used for anesthesia, none of them covered by an FDA-approved drug application. The site also offered these prescription drugs without requiring a prescription.
What FDA found
The website sold ketamine drugs that have no FDA-approved application.
FD&C Act sections 301(d) and 505(a) (21 U.S.C. 331(d), 355(a))The labeling did not carry adequate directions for use, and as prescription drugs for conditions a layperson cannot self-treat, such directions cannot be written.
FD&C Act section 502(f)(1) (21 U.S.C. 352(f)(1)); 21 CFR 201.115(a)The website offered prescription drugs for sale without requiring a prescription.
FD&C Act sections 503(b)(1) and 301(k) (21 U.S.C. 353(b)(1), 331(k))Website claims that the products are used for anesthesia and to treat depression show they are drugs intended for human use.
FD&C Act section 201(g) (21 U.S.C. 321(g)); 21 CFR 201.128The nasal spray is sold outside the restricted safety program (REMS) that FDA requires for the approved esketamine nasal spray, which must be given in certified settings with two hours of monitoring.
What FDA wants
FDA tells the company to stop offering any unapproved and misbranded drugs for sale to U.S. consumers right away. It must send a written response within 15 business days describing the corrections made, how recurrence will be prevented, and supporting documents, citing reference MARCS-CMS 725154.
Who should pay attention
- online sellers and telehealth companies offering ketamine products
- clinics and compounding pharmacies marketing ketamine for depression
- payment processors and platforms hosting websites that sell prescription drugs
This is a summary. Read the original letter on fda.gov.